Dovitinib (TKI-258) Dilactic Acid is primarily used in cancer treatment, particularly for targeting advanced or metastatic renal cell carcinoma. It functions as a multi-targeted tyrosine kinase inhibitor, effectively blocking pathways involved in tumor growth and angiogenesis. This compound is also being explored for its potential in treating other cancers, such as breast and gastrointestinal stromal tumors, due to its ability to inhibit multiple kinases associated with cancer progression. Its application in clinical trials has shown promise in improving patient outcomes by slowing disease progression and enhancing the efficacy of combination therapies.